NAMS
NewAmsterdam Pharma Co N.V.
+0.77 (+3.64%)21.95USD789K成交股數–市值–本益比(近四季)–股價營收比-80.7%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。外國發行人(20-F)通常只申報半年或年度,逐季會有缺。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 3.7M-81% | 3.0M+2% | 32K-100% | 348K-85% | 19.1M+1267% | 3.0M+271% | 29.1M+890% | 2.3M+33% | 1.4M | 803K | 2.9M | 1.7M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 41.7M | 38.0M | 38.6M | 31.0M | 27.5M | 44.8M | 35.7M | 38.4M | 42.4M | 41.3M | 43.4M | 34.3M |
| 銷售管理費用 | 26.9M | 23.5M | 27.4M | 24.5M | 27.3M | 27.2M | 18.4M | 16.5M | 14.5M | 10.6M | 9.1M | 9.9M |
| 營業利益 | −64.9M+82% | −58.4M-15% | −66.0M+164% | −55.1M+5% | −35.6M-36% | −68.9M+35% | −25.0M-50% | −52.6M+24% | −55.5M | −51.1M | −49.6M | −42.5M |
| 營業利益率 | -1,752.6% | -1,921.7% | -206,187.5% | -15,845.7% | -186.1% | -2,314.5% | -85.9% | -2,306.9% | -3,960.2% | -6,360.4% | -1,685.1% | -2,474.2% |
| 稅後淨利 | −64.1M+269% | −48.4M+23% | −74.1M+345% | −72.0M+85% | −17.4M-81% | −39.5M-20% | −16.6M-65% | −39.0M+2% | −93.8M | −49.6M | −47.1M | −38.3M |
| 淨利率 | -1,732.9% | -1,593.5% | -231,575.0% | -20,691.1% | -90.7% | -1,327.3% | -57.2% | -1,711.6% | -6,692.9% | -6,171.6% | -1,602.6% | -2,230.1% |
| 稀釋 EPS | -0.52+247% | -0.40+18% | -0.62+244% | -0.61+49% | -0.15-86% | -0.34-43% | -0.18-68% | -0.41-13% | -1.06 | -0.60 | -0.57 | -0.47 |
| 稀釋股數 | 123M | 122M | 118M | 119M | 119M | 116M | 94.8M | 94.7M | 88.4M | 82.2M | 82.5M | 82.1M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 424M | 458M | 490M | 538M | 564M | 748M | 423M | – | – | 340M | – | – |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 704M | 733M | 769M | 786M | 815M | 818M | 439M | 447M | 488M | 347M | – | – |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 73.0M | 67.4M | 85.9M | 58.4M | 36.6M | 41.1M | 60.3M | 59.3M | 76.7M | 58.7M | – | – |
| 股東權益 | 631M | 665M | 683M | 728M | 778M | 777M | 379M | 387M | 412M | 288M | 332M | 373M |
| 負債比 | 10.4% | 9.2% | 11.2% | 7.4% | 4.5% | 5.0% | 13.7% | 13.3% | 15.7% | 16.9% | – | – |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −30.6M-16% | – | – | – | −36.5M | – | – | −54.6M | – | – | – |
| 資本支出 | – | 38K | – | – | – | 16K | – | – | 385K | – | – | – |
| 自由現金流 | – | −30.6M-16% | – | – | – | −36.5M | – | – | −55.0M | – | – | – |
| 折舊攤銷 | 89K | 62K | −64K | 125K | 107K | 52K | 89K | 66K | 15K | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -1,008.0% | – | – | – | -1,225.1% | – | – | -3,924.8% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 22.5M | -50.6% | −203M | -902.1% | -1.72 | −148M |
| FY2024 | 45.6M | +223.4% | −242M | -531.1% | -2.56 | −159M |
| FY2023 | 14.1M | -86.3% | −177M | -1,256.2% | -2.15 | −141M |
| FY2022 | 103M | – | −22.6M | -22.0% | -1.19 | 10.4M |
| FY2021 | – | – | −41.8M | –% | -3.81 | −29.5M |